Inactivation of p53 Provides a Competitive Advantage to Del(5q) Myelodysplastic Syndrome Hematopoietic Stem Cells During Inflammation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
Haematologica 2023 Apr 27;[EPub Ahead of Print], T Muto, CS Walker, P Agarwal, E Vick, A Sampson, K Choi, M Niederkorn, C Ishikawa, K Hueneman, M Varney, DT StarczynowskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.